RxDoctor Payments Data

Diana Portilla, MD

Internal Medicine · Englewood, NJNPI 1487769923

Payments from drug & device makers

$15,058in general payments, 2019–2025

Across 770 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$906
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$2522%
  • Food & beverage$14,67097%
  • Education$1361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,058 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$92,187
Medicare patients
112
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$103,592
OzempicSemaglutide54$76,604
ProliaDenosumab28$45,778
EliquisApixaban25$36,007
Bydureon BciseExenatide Microspheres12$28,403
JanuviaSitagliptin Phosphate18$22,757
RybelsusSemaglutide12$21,968
FarxigaDapagliflozin Propanediol18$21,724
XareltoRivaroxaban17$19,921
UbrelvyUbrogepant11$15,625
Repatha SureclickEvolocumab20$11,247
Emgality PenGalcanezumab-Gnlm16$10,104
VascepaIcosapent Ethyl18$8,611
Janumet XrSitagliptin Phos/Metformin Hcl13$6,970
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,585$103,59284 claims
Novo NordiskOzempic, Rybelsus$1,081$98,57266 claims
AmgenProlia$3,184$45,77828 claims
PfizerEliquis$227$36,00725 claims
MerckJanuvia, Janumet Xr$336$29,72831 claims
AstraZenecaFarxiga$1,611$21,72418 claims
Johnson & JohnsonXarelto$446$19,92117 claims
AbbVieUbrelvy$1,274$15,62511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →